Was Paul Wood wrong about pre-capillary pulmonary hypertension protecting against pulmonary congestion in left heart disease?
- PMID: 35796482
- DOI: 10.1093/eurheartj/ehac176
Was Paul Wood wrong about pre-capillary pulmonary hypertension protecting against pulmonary congestion in left heart disease?
Conflict of interest statement
Conflict of interest: M.M.H. has received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD, and Pfizer. S.R. has received fees for lectures and/or consultations from Abbott, Acceleron, Actelion, Bayer, BMS, Gilead, GSK, Janssen, MSD, Novartis, Pfizer, United Therapeutics, and Vifor; and research grants to his institution from AstraZeneca, Actelion, Bayer Janssen, and Novartis.
Comment on
-
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.Eur Heart J. 2022 Sep 21;43(36):3417-3431. doi: 10.1093/eurheartj/ehac184. Eur Heart J. 2022. PMID: 35796488 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
